161 related articles for article (PubMed ID: 23696113)
41. Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland.
Bähler C; Schoepfer AM; Vavricka SR; Brüngger B; Reich O
Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):916-925. PubMed ID: 28471826
[TBL] [Abstract][Full Text] [Related]
42. How expensive is inflammatory bowel disease? A critical analysis.
Odes S
World J Gastroenterol; 2008 Nov; 14(43):6641-7. PubMed ID: 19034966
[TBL] [Abstract][Full Text] [Related]
43. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease.
Ananthakrishnan AN; McGinley EL; Binion DG
Gut; 2008 Feb; 57(2):205-10. PubMed ID: 17905821
[TBL] [Abstract][Full Text] [Related]
44. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
Pedersen N
Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
[TBL] [Abstract][Full Text] [Related]
45. An integrated model of care for inflammatory bowel disease sufferers in Australia: development and the effects of its implementation.
Mikocka-Walus AA; Turnbull D; Holtmann G; Andrews JM
Inflamm Bowel Dis; 2012 Aug; 18(8):1573-81. PubMed ID: 22179943
[TBL] [Abstract][Full Text] [Related]
46. Out-of-pocket Cost Burden in Pediatric Inflammatory Bowel Disease: A Cross-sectional Cohort Analysis.
Sin AT; Damman JL; Ziring DA; Gleghorn EE; Garcia-Careaga MG; Gugig RR; Hunter AK; Burgis JC; Bass DM; Park KT
Inflamm Bowel Dis; 2015 Jun; 21(6):1368-77. PubMed ID: 25839776
[TBL] [Abstract][Full Text] [Related]
47. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort.
Burisch J; Pedersen N; Čuković-Čavka S; Brinar M; Kaimakliotis I; Duricova D; Shonová O; Vind I; Avnstrøm S; Thorsgaard N; Andersen V; Krabbe S; Dahlerup JF; Salupere R; Nielsen KR; Olsen J; Manninen P; Collin P; Tsianos EV; Katsanos KH; Ladefoged K; Lakatos L; Björnsson E; Ragnarsson G; Bailey Y; Odes S; Schwartz D; Martinato M; Lupinacci G; Milla M; De Padova A; D'Incà R; Beltrami M; Kupcinskas L; Kiudelis G; Turcan S; Tighineanu O; Mihu I; Magro F; Barros LF; Goldis A; Lazar D; Belousova E; Nikulina I; Hernandez V; Martinez-Ares D; Almer S; Zhulina Y; Halfvarson J; Arebi N; Sebastian S; Lakatos PL; Langholz E; Munkholm P;
Gut; 2014 Apr; 63(4):588-97. PubMed ID: 23604131
[TBL] [Abstract][Full Text] [Related]
48. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.
Bassi A; Dodd S; Williamson P; Bodger K
Gut; 2004 Oct; 53(10):1471-8. PubMed ID: 15361497
[TBL] [Abstract][Full Text] [Related]
49. [Cost of illness of inflammatory bowel disease in Germany].
Schnorbach MT; Kruis W
Z Gastroenterol; 2021 Nov; 59(11):1173-1188. PubMed ID: 32869213
[TBL] [Abstract][Full Text] [Related]
50. Prospective population-based cohort of inflammatory bowel disease in the biologics era: Disease course and predictors of severity.
Niewiadomski O; Studd C; Hair C; Wilson J; Ding NS; Heerasing N; Ting A; McNeill J; Knight R; Santamaria J; Prewett E; Dabkowski P; Dowling D; Alexander S; Allen B; Popp B; Connell W; Desmond P; Bell S
J Gastroenterol Hepatol; 2015 Sep; 30(9):1346-53. PubMed ID: 25867770
[TBL] [Abstract][Full Text] [Related]
51. [Employees with chronic diseases - additional results of randomized controlled trial among adult members of a German statutory health insurance with inflammatory bowel diseases].
Langbrandtner J; Raspe H; Hüppe A
Z Gastroenterol; 2016 Feb; 54(2):139-45. PubMed ID: 26854833
[TBL] [Abstract][Full Text] [Related]
52. Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database.
Kurti Z; Vegh Z; Golovics PA; Fadgyas-Freyler P; Gecse KB; Gonczi L; Gimesi-Orszagh J; Lovasz BD; Lakatos PL
Dig Liver Dis; 2016 Nov; 48(11):1302-1307. PubMed ID: 27481587
[TBL] [Abstract][Full Text] [Related]
53. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review.
Park KT; Bass D
Inflamm Bowel Dis; 2011 Jul; 17(7):1603-9. PubMed ID: 21053357
[TBL] [Abstract][Full Text] [Related]
54. The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study.
Ott C; Obermeier F; Thieler S; Kemptner D; Bauer A; Schölmerich J; Rogler G; Timmer A
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):917-23. PubMed ID: 18794607
[TBL] [Abstract][Full Text] [Related]
55. Quality of Care and Outcomes Among Hospitalized Inflammatory Bowel Disease Patients: A Multicenter Retrospective Study.
Nguyen GC; Murthy SK; Bressler B; Lam MCW; Alali A; Toumi A; Reinglas J; Rampersad A; Weizman AV; Afif W;
Inflamm Bowel Dis; 2017 May; 23(5):695-701. PubMed ID: 28426451
[TBL] [Abstract][Full Text] [Related]
56. Inflammatory bowel disease in pediatric patients: Characteristics of newly diagnosed patients from the CEDATA-GPGE Registry.
Buderus S; Scholz D; Behrens R; Classen M; De Laffolie J; Keller KM; Zimmer KP; Koletzko S;
Dtsch Arztebl Int; 2015 Feb; 112(8):121-7. PubMed ID: 25759978
[TBL] [Abstract][Full Text] [Related]
57. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation.
Odes S; Vardi H; Friger M; Wolters F; Russel MG; Riis L; Munkholm P; Politi P; Tsianos E; Clofent J; Vermeire S; Monteiro E; Mouzas I; Fornaciari G; Sijbrandij J; Limonard C; Van Zeijl G; O'morain C; Moum B; Vatn M; Stockbrugger R;
Gastroenterology; 2006 Sep; 131(3):719-28. PubMed ID: 16952541
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
[TBL] [Abstract][Full Text] [Related]
59. [Rehabilitation in geriatric patients after ischemic stroke--a comparison of 2 organisational systems in Germany using claims data of a statutory health insurance fund].
Abbas S; Ihle P; Hein R; Schubert I
Rehabilitation (Stuttg); 2013 Dec; 52(6):375-82. PubMed ID: 23824567
[TBL] [Abstract][Full Text] [Related]
60. [Costs of ambulant care for patients with inflammatory bowel disease in general practice].
Beiche A; König HH; Ebinger M; Matysiak-Klose D; Braun V; Leidl R
Z Gastroenterol; 2003 Jun; 41(6):527-36. PubMed ID: 12806538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
